Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France lists more innovative/costly device to be paid from separate budgets:

This article was originally published in Clinica

Executive Summary

Two decrees have been published in the French Journal officiel in November determining medical devices that will be paid for in France over and above the standard stay group tariffs (GHS - a single tariff payment by the government to cover the costs of an entire medical procedure). Products that will be paid for separately, as listed in the decrees published on November 22 and November 1, are certain types of the following: urogenital implants; heart valves; defibrillators; vascular implants; and pacemakers. Industry had lobbied successfully for some of the more costly or innovative products to be paid for separately from the GHS, as it feared that hospitals would otherwise be unable to meet the costs of such products from already-squeezed diagnosis-related group style budgets.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel